ERBB2 and carcinoma: Hombach et al. [93] constructed a CD19 CAR T cell that is readdressed against ErbB2+ carcinoma cells by fusing a protein, herceptin-derived anti-ErbB2 scFv 4D5, linked to the CD19 exodomain.